-
How Obesity Affects Drugs Used to Treat GI Cancers
16 Dec 2025 16:57 GMT
… When toxicities develop, dose … cancer, gastrointestinal stromal tumors, hepatocellular carcinoma … treat GI cancers. Guidance on the dosing of cancer drugs … Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection. Drug …
-
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
25 Nov 2025 00:00 GMT
… novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors ( … clinically available to treat SDH-deficient GISTs. … development program to bring a safe and effective new treatment … FDA in the US. About Ascentage Pharma Ascentage Pharma …
-
<![CDATA[Breaking Down Gastrointestinal Stromal Tumor Basics]]>
20 Nov 2025 23:12 GMT
… the basics of gastrointestinal stromal tumors (GIST), highlighting … gastrointestinal stromal tumor (GIST) is and how it is typically treated?
Gupta: Gastrointestinal stromal tumor … time.
What new treatment options, like TKIs … TKI have been developed, and now, …
-
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
09 Dec 2025 00:45 GMT
… a novel drug developed by Ascentage Pharma and represents the … dehydrogenase (SDH)-deficient gastrointestinal stromal tumors. Notably, the POLARIS-1 … an FDA-cleared, global registrational Phase III trial, … inhibitor for the treatment of various hematologic …
-
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
09 Dec 2025 00:45 GMT
… (SDH)- deficient gastrointestinal stromal tumors (GIST). Ascentage Pharma has signed an exclusive … , some patients develop drug resistance or intolerance during treatment with TKIs. Prior … conducting an FDA-cleared, global registrational Phase III trial, or …
-
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
09 Dec 2025 00:45 GMT
… a novel drug developed by Ascentage Pharma and represents … (SDH)-deficient gastrointestinal stromal tumors (GIST). Ascentage Pharma has signed an … long-term treatment, reinforcing the drug’s established … an FDA-cleared, global registrational Phase III trial, …
-
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
08 Dec 2025 12:30 GMT
… .S. Food and Drug Administration (FDA) for bezuclastinib in … will become an important treatment option for this patient … company focused on developing precision therapies for … in patients with advanced gastrointestinal stromal tumors (GIST), a type …
-
<![CDATA[Cogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.]]>
13 Nov 2025 13:51 GMT
… imatinib-resistant or intolerant gastrointestinal stromal tumors (GIST). The first … submit a New Drug Application in 2026. … first-line treatment, resistance inevitably develops, often through … sunitinib, the PEAK trial leveraged complementary mechanisms …
-
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
10 Nov 2025 12:00 GMT
… S. Food and Drug Administration (FDA) for bezuclastinib … from the PEAK trial at an upcoming … discontinued study treatment(s) due to treatment related … gastrointestinal stromal tumors (GIST). In addition to bezuclastinib, the Cogent Research Team is developing …
-
<![CDATA[Research Underway In SDH-Deficient GIST Treatment]]>
27 Nov 2025 04:24 GMT
… treatment for patients with succinate dehydrogenase (SDH) deficient gastrointestinal stromal tumors … development program to bring a safe and effective new treatment … Pharma Group International Inc. News release; Nov. 24, 2025.
“Gastrointestinal Stromal Tumor …
About
© 1995-2025